Charles River Laboratories Announces Leadership Transition

Details

announced a leadership transition where Mr. James C. Foster, the current Chairman, President, and Chief Executive Officer, will step down as CEO and Chairman effective May 5, 2026. Ms. Birgit Girshick, the current Chief Operating Officer, will succeed him as CEO. The Board size will increase from 11 to 12 to accommodate Ms. Girshick's appointment as a director, effective at the 2026 Annual Meeting of Shareholders. The Company also announced compensation changes for both Mr. Foster and Ms. Girshick.

Items reported

About Charles River Laboratories International, Inc.

Charles River Laboratories International, Inc. provides essential services to the pharmaceutical, biotechnology, and life sciences industries. The company specializes in preclinical and clinical lab services, offering clients a comprehensive suite of drug discovery and development services that expedite the process of getting new drugs and therapies to the market. Notably, Charles River's facilities offer expertise in the fields of oncology, immunology, and neuroscience, making it a critical partner for companies working in these therapeutic areas. The firm operates globally, enhancing its customers' ability to operate internationally through its wide network of laboratories and testing facilities. By enabling more efficient drug development cycles and reducing the time to market for new therapies, Charles River Laboratories plays a crucial role in the advancement of medical science and patient care worldwide. The company's commitment to high standards of animal welfare and ethical practices further underscores its reputation as a leader in quality and reliability within the research community.